ProfileGDS5678 / 1426653_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 85% 85% 83% 86% 87% 89% 85% 85% 85% 85% 85% 87% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.3726485
GSM967853U87-EV human glioblastoma xenograft - Control 26.4080285
GSM967854U87-EV human glioblastoma xenograft - Control 36.3829985
GSM967855U87-EV human glioblastoma xenograft - Control 46.2829783
GSM967856U87-EV human glioblastoma xenograft - Control 56.5362286
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.408987
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7855889
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3598385
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.3601285
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3734685
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.362185
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3574585
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.7064287
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5091786